- Home
- GMM vs BRNS Comparison
GMM vs BRNS Comparison
Compare GMM & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- BRNS
- Stock Information
- Founded
- GMM 2017
- BRNS 2016
- Country
- GMM China
- BRNS United Kingdom
- Employees
- GMM N/A
- BRNS N/A
- Industry
- GMM
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- GMM
- BRNS Health Care
- Exchange
- GMM Nasdaq
- BRNS Nasdaq
- Market Cap
- GMM 57.9M
- BRNS 55.9M
- IPO Year
- GMM 2023
- BRNS 2021
- Fundamental
- Price
- GMM $1.54
- BRNS $0.73
- Analyst Decision
- GMM
- BRNS Strong Buy
- Analyst Count
- GMM 0
- BRNS 1
- Target Price
- GMM N/A
- BRNS $4.00
- AVG Volume (30 Days)
- GMM 17.5K
- BRNS 138.9K
- Earning Date
- GMM 08-18-2025
- BRNS 11-07-2025
- Dividend Yield
- GMM N/A
- BRNS N/A
- EPS Growth
- GMM N/A
- BRNS N/A
- EPS
- GMM 1.79
- BRNS N/A
- Revenue
- GMM $48,171,048.00
- BRNS N/A
- Revenue This Year
- GMM N/A
- BRNS N/A
- Revenue Next Year
- GMM N/A
- BRNS N/A
- P/E Ratio
- GMM $0.89
- BRNS N/A
- Revenue Growth
- GMM 41.74
- BRNS 1766.46
- 52 Week Low
- GMM $1.41
- BRNS $0.64
- 52 Week High
- GMM $4.97
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- GMM 37.89
- BRNS 32.84
- Support Level
- GMM $1.41
- BRNS $0.75
- Resistance Level
- GMM $1.62
- BRNS $0.80
- Average True Range (ATR)
- GMM 0.09
- BRNS 0.10
- MACD
- GMM -0.00
- BRNS -0.00
- Stochastic Oscillator
- GMM 43.90
- BRNS 13.81
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.